|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192990-03
|
$171,681
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
(1) Intestinal Organoid Models for APC LOH
|
1R21CA208638-01
|
$232,195
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-07
|
$730,767
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ1) Epigenetic effects of the premalignant field
|
1R01CA208620-01
|
$357,464
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
1R01CA208644-01
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ4) Elucidating Determinants of Susceptibility to Tumorigenesis in the Skin
|
1R21CA208298-01
|
$217,016
|
RAMSEY, MATTHEW
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
1R01CA205632-01
|
$469,489
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ8) BONE MARROW-ON-A-CHIP"":AN INVITRO 3D MODEL OF BREAST CANCER DORMANCY
|
1R21CA208519-01
|
$165,844
|
GEORGE, STEVEN
|
WASHINGTON UNIVERSITY
|
|
(PQ9) Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection
|
1R21CA208631-01
|
$251,120
|
LANNIGAN, DEBORAH
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
7R21CA205437-02
|
$152,333
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.
|
1R21CA205437-01
|
$51,247
|
WANING, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-03
|
$560,492
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancer
|
4R01CA180277-04
|
$307,375
|
LI, XIN
|
NEW YORK UNIVERSITY
|
|
(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu
|
5R01CA185039-03
|
$373,436
|
JAN, LILY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
7R01CA184820-03
|
$386,650
|
DUBOIS, RAYMOND
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
(PQA2) A NEW TOOL FOR CANCER PROGNOSTICATION BASED ON ALTERING VASCULAR HOMOEOSTASIS
|
5R21CA194634-02
|
$173,456
|
SEN, ARINDAM
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
|
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
|
5R01CA180070-05
|
$339,116
|
HEBER-KATZ, ELLEN
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
5R01CA190122-03
|
$571,080
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer
|
5R01CA179991-04
|
$282,056
|
IACOBUZIO-DONAHUE, CHRISTINE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
|
4R01CA180149-04
|
$560,735
|
AGUS, DAVID
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQB6)Elucidating metastasis by real-time monitoring and tagging of CTCs in GEMMs
|
5R01CA184956-03
|
$600,940
|
MANALIS, SCOTT
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-03
|
$1,005,598
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
|
5R01CA190027-03
|
$394,250
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS
|
5R01CA185138-03
|
$490,842
|
HWANG, EUN-SIL
|
DUKE UNIVERSITY
|
|
(PQC4) Fate of cells disseminating from human breast cancer xenografts
|
4R01CA180039-04
|
$328,888
|
WERB, ZENA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In Situ
|
5R01CA194697-02
|
$347,700
|
ZHANG, SIYUAN
|
UNIVERSITY OF NOTRE DAME
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-03
|
$696,509
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTS
|
4R01CA180061-04
|
$410,757
|
WOODWARD, WENDY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-07
|
$1,293,750
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-03
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
|
1R01CA201250-01A1
|
$698,899
|
LARSON, STEVEN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
15-PGDH in Cholangiocarcinogenesis
|
2R01CA102325-10A1
|
$344,269
|
WU, TONG
|
TULANE UNIVERSITY OF LOUISIANA
|
|
2/2 Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192992-03
|
$164,190
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-07
|
$997,277
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
3P20CA192976-02S1
|
$20,000
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-03
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
2U54CA118623-11
|
$1,134,399
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
27-hydroxycholesterol as a link between obesity and breast cancer pathogenesis
|
5R00CA172357-05
|
$240,780
|
NELSON, ERIK
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
2U54CA118948-11
|
$1,337,658
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
1R01CA195443-01A1
|
$255,216
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
|
3D-Adhesion Stromagenesis in Cancer Permissiveness
|
3R01CA113451-10S1
|
$67,588
|
CUKIERMAN, EDNA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
3D-Adhesion Stromagenesis in Cancer Permissiveness
|
4R01CA113451-10
|
$333,377
|
CUKIERMAN, EDNA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
A chemopreventive approach of targeting breast cancer stem cells
|
5R03CA198614-02
|
$79,250
|
DIMRI, MANJARI
|
GEORGE WASHINGTON UNIVERSITY
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-08
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A micro Hall chip for circulating microvesicle based cancer monitoring
|
5R21CA182336-03
|
$199,268
|
ISSADORE, DAVID
|
UNIVERSITY OF PENNSYLVANIA
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$134,092
|
Kelly Siebenlist, Kathleen
|
CCR (NCI)
|
|
A nanosystem for tumor treatment and imaging
|
5R01CA188883-03
|
$404,625
|
RUOSLAHTI, ERKKI
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
1R01CA196631-01A1
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
A new imaging approach to radiotherapy planning for lung cancer
|
5R01CA193050-02
|
$152,104
|
RIZI, RAHIM
|
UNIVERSITY OF PENNSYLVANIA
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
7R01CA166894-04
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|